Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
3
result(s) for
"Bräuninger, Susanne"
Sort by:
Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
by
Karpova, Darja
,
Dembowski, Klaus
,
Douglas, Garry
in
Biomedical and Life Sciences
,
Biomedicine
,
Cell Differentiation - drug effects
2017
Background
Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CSF.
Methods
Healthy male volunteer donors with a documented average mobilization response to G-CSF received, following ≥6 weeks wash-out, a 1–2 h infusion of 500–2500 µg/kg of balixafortide. Safety, tolerability, pharmacokinetics and pharmacodynamics were assessed.
Results
Balixafortide was well tolerated and rated favorably over G-CSF by subjects. At all doses tested balixafortide mobilized HSPC. In the dose range between 1500 and 2500 µg/kg mobilization was similar, reaching 38.2 ± 2.8 CD34 + cells/µL (mean ± SEM). Balixafortide caused mixed leukocytosis in the mid-20 K/µL range. B-lymphocytosis was more pronounced, whereas neutrophilia and monocytosis were markedly less accentuated with balixafortide compared to G-CSF. At the 24 h time point, leukocytes had largely normalized.
Conclusions
Balixafortide is safe, well tolerated, and induces efficient mobilization of HSPCs in healthy male volunteers. Based on experience with current apheresis technology, the observed mobilization at doses ≥1500 µg/kg of balixafortide is predicted to yield in a single apheresis a standard dose of 4× 10E6 CD34+ cells/kg from most individuals donating for an approximately weight-matched recipient. Exploration of alternative dosing regimens may provide even higher mobilization responses.
Trial Registration
European Medicines Agency (EudraCT-Nr. 2011-003316-23) and
clinicaltrials.gov
(NCT01841476)
Journal Article
Molecular consequences of SARS-CoV-2 liver tropism
2022
Extrapulmonary manifestations of COVID-19 have gained attention due to their links to clinical outcomes and their potential long-term sequelae
1
. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) displays tropism towards several organs, including the heart and kidney. Whether it also directly affects the liver has been debated
2
,
3
. Here we provide clinical, histopathological, molecular and bioinformatic evidence for the hepatic tropism of SARS-CoV-2. We find that liver injury, indicated by a high frequency of abnormal liver function tests, is a common clinical feature of COVID-19 in two independent cohorts of patients with COVID-19 requiring hospitalization. Using autopsy samples obtained from a third patient cohort, we provide multiple levels of evidence for SARS-CoV-2 liver tropism, including viral RNA detection in 69% of autopsy liver specimens, and successful isolation of infectious SARS-CoV-2 from liver tissue postmortem. Furthermore, we identify transcription-, proteomic- and transcription factor-based activity profiles in hepatic autopsy samples, revealing similarities to the signatures associated with multiple other viral infections of the human liver. Together, we provide a comprehensive multimodal analysis of SARS-CoV-2 liver tropism, which increases our understanding of the molecular consequences of severe COVID-19 and could be useful for the identification of organ-specific pharmacological targets.
Wanner et al. demonstrate SARS-CoV-2 liver tropism and identify transcriptional and proteomic profiles of SARS-CoV-2 liver samples that show similarities to previously characterized hepatotropic viruses.
Journal Article
Die Positionen der Parteien zur Bundestagswahl 2021: Ergebnisse des Open Expert Surveys
by
Bräuninger, Thomas
,
Kurella, Anna-Sophie
,
Jankowski, Michael
in
Bundestagswahl 2021
,
Expert survey
,
Expertenbefragung
2022
Diese Research Note berichtet zentrale Ergebnisse des Open Expert Surveys 2021 (OES21). In diesem Expert:innen-Survey, der vor der Bundestagswahl 2021 durchgeführt wurde, haben mehr als 300 Politikwissenschaftler:innen die wichtigsten Parteien entlang zentraler politischer Sachfragen verortet und deren Wichtigkeit für die jeweilige Partei geschätzt. Der OES21 unterscheidet sich von gängigen Expert:innenbefragungen in zweierlei Hinsicht. Zum einen umfasst der Survey zahlreiche themenspezifische Items, die in anderen Befragungen bislang keine Beachtung fanden. Zum anderen ist die Anzahl der Expert:innen sehr hoch, wodurch Zusammenhänge in der Positionierung auf Ebene der einzelnen Expert:innen analysiert werden können.
Journal Article